Yasong Lu

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses
    Yasong Lu
    MS 220 4546, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 342:366-75. 2012
  2. doi request reprint Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors
    Yasong Lu
    Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 339:922-34. 2011
  3. doi request reprint Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor
    Antonia F Stepan
    Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 55:3414-24. 2012
  4. doi request reprint Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses
    Yasong Lu
    Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT 06340, USA Yasong Lu pfizer com
    Neurodegener Dis 12:36-50. 2013
  5. doi request reprint Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors
    Antonia F Stepan
    Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
    J Med Chem 54:7772-83. 2011

Collaborators

Detail Information

Publications5

  1. doi request reprint Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses
    Yasong Lu
    MS 220 4546, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 342:366-75. 2012
    ..We further discuss the implications of our findings to drug discovery and development with regard to preclinical PK/PD characterization and clinical prediction of Aβ lowering in the brain...
  2. doi request reprint Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors
    Yasong Lu
    Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 339:922-34. 2011
    ..Concurrently, the necessity and utilities of PK/PD modeling for rational interpretation of Aβ data are established...
  3. doi request reprint Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor
    Antonia F Stepan
    Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 55:3414-24. 2012
    ....
  4. doi request reprint Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses
    Yasong Lu
    Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT 06340, USA Yasong Lu pfizer com
    Neurodegener Dis 12:36-50. 2013
    ..Interpretation and translation of the pharmacokinetic (PK)/pharmacodynamic (PD) relationship for these compounds is complicated by the relatively slow Aβ turnover process in these compartments...
  5. doi request reprint Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors
    Antonia F Stepan
    Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
    J Med Chem 54:7772-83. 2011
    ..As such, the study also illustrates the improvement in druglikeness of molecules through the use of the oxetane motif...